Systemic weakness after therapeutic injections of botulinum toxin A: A case series and review of the literature

Clinical Neuropharmacology

Volumn 33, Issue 5, 2010, Pages 243-247

  Crowner, Beth E ^a   Torres Russotto, Diego ^b   Carter, Alexandre R ^a   Racette, Brad A ^a,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c American Parkinson Disease Association Advanced Center for Parkinson Research   (United States)

Author keywords

botulinum toxin A; botulism; dose response relationship; idiosyncratic adverse reaction; spasticity

Indexed keywords

BACLOFEN; BOTULINUM TOXIN A;

ADOLESCENT; ADULT; ARTICLE; BODY WEIGHT; CASE REPORT; DIPLOPIA; DRUG TOLERABILITY; DYSARTHRIA; DYSPHAGIA; DYSPHONIA; ELECTROMYOGRAPHY; FATIGUE; FEMALE; FOLLOW UP; HUMAN; LIMB WEAKNESS; MALE; MUSCLE HYPOTONIA; MUSCLE WEAKNESS; NEUROLOGIC EXAMINATION; OFF LABEL DRUG USE; PRIORITY JOURNAL; PTOSIS; SPASTICITY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTI-DYSKINESIA AGENTS; BOTULINUM TOXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSTONIA; ELECTROMYOGRAPHY; FEMALE; HUMANS; INJECTIONS, INTRAMUSCULAR; MALE; MUSCLE WEAKNESS; YOUNG ADULT;

EID: 77958004839     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181f5329e     Document Type: Article

References (32)

1. Berweck S, Heinen F. Use of botulinum toxin in pediatric spasticity (cerebral palsy). Mov Disord 2004;19(Suppl 8):S162YS167.
2. Brin MF. Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve Suppl 1997;6:S146YS168.
3. Carruthers J, Carruthers A. Complications of botulinum toxin type A. Facial Plast Surg Clin North Am 2007;15(1):51Y54, vi.
4. Koman LA, Mooney JF III, Smith BP, et al. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: a randomized, double-blind, placebo-controlled trial. BOTOX Study Group. J Pediatr Orthop 2000;20(1):108Y115.
5. Koman LA, Brashear A, Rosenfeld S, et al. Botulinum toxin type a neuromuscular blockade in the treatment of equinus foot deformity in cerebral palsy: a multicenter, open-label clinical trial. Pediatrics 2001;108(5): 1062Y1071.
6. Lange DJ, Brin MF, Warner CL, et al. Distant effects of local injection of botulinum toxin. Muscle Nerve 1987;10(6):552Y555.
7. Sanders DB, Massey EW, Buckley EG. Botulinum toxin for blepharospasm: single-fiber EMG studies. Neurology 1986;36(4): 545Y547.
8. Girlanda P, Vita G, Nicolosi C, et al. Botulinum toxin therapy: distant effects on neuromuscular transmission and autonomic nervous system. J Neurol Neurosurg Psychiatry 1992;55(9):844Y845.
9. Garner CG, Straube A, Witt TN, et al. Time course of distant effects of local injections of botulinum toxin. Mov Disord 1993;8(1):33Y37.
10. Bakheit AM, Ward CD, McLellan DL. Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: a report of two cases. J Neurol Neurosurg Psychiatry 1997;62(2):198.
11. Bhatia KP, Munchau A, Thompson PD, et al. Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases. J Neurol Neurosurg Psychiatry 1999;67(1):90Y93.
12. McMahon MA. Systemic weakness after botulinum toxin type A in a child with cerebral palsy: a case report. Arch Phys Med Rehabil 2002;83(11):1675.
13. Wyndaele JJ, Van Dromme SA. Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity. Spinal Cord 2002;40(11):599Y600.
14. Duffey P, Brown C. Iatrogenic botulism in an amateur weight-lifter. Mov Disord 2006;21(7):1056.
15. Goldstein EM. Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity. J Child Neurol 2006;21(3):189Y192.
16. Howell K, Selber P, Graham HK, et al. Botulinum neurotoxin A: an unusual systemic effect. J Paediatr Child Health 2007;43(6):499Y501.
17. Varghese-Kroll E, Elovic EP. Contralateral weakness and fatigue after high-dose botulinum toxin injection for management of poststroke spasticity. Am J Phys Med Rehabil 2009;88(6):495Y499.
18. McMahon MA. Systemic weakness after botulinum toxin type A in a child with cerebral palsy: a case report. Arch Phys Med Rehabil 2002;83(11):1675.
19. Howell K, Selber P, Graham HK, et al. Botulinum neurotoxin A: an unusual systemic effect. J Paediatr Child Health 2007;43(6):499Y501.
20. Varghese-Kroll E, Elovic EP. Contralateral weakness and fatigue after high-dose botulinum toxin injection for management of poststroke spasticity. Am J Phys Med Rehabil 2009;88(6):495Y499.
21. LeWitt PA, Trosch RM. Idiosyncratic adverse reactions to intramuscular botulinum toxin type A injection. Mov Disord 1997;12(6):1064Y1067.
22. Willis AW, Crowner B, Brunstrom JE, et al. High dose botulinum toxin A for the treatment of lower extremity hypertonicity in children with cerebral palsy. Dev Med Child Neurol 2007;49(11):818Y822.
23. Koman LA, Mooney JF III, Smith BP, et al. Management of spasticity in cerebral palsy with botulinum-A toxin: report of a preliminary, randomized, double-blind trial. J Pediatr Orthop 1994;14(3):299Y303.
24. Heinen F, Schroeder AS, Fietzek U, et al. When it comes to botulinum toxin, children and adults are not the same: multimuscle option for children with cerebral palsy. Mov Disord 2006;21(11):2029Y2030.
25. Russman BS, Tilton A, Gormley ME Jr. Cerebral palsy: a rational approach to a treatment protocol, and the role of botulinum toxin in treatment. Muscle Nerve Suppl 1997;6:S181YS193.
26. Delgado MR. The use of botulinum toxin type A in children with cerebral palsy: a retrospective study. Eur J Neurol 1999;6(Suppl 4): S11YS18.
27. Gormley ME, Gaebler-Spira D, Delgado MR. Use of botulinum toxin type A in pediatric patients with cerebral palsy: a three-center retrospective chart review. J Child Neurol 2001;16(2):113Y118.
28. Odergren T, Hjaltason H, Kaakkola S, et al. A double blind, randomised, parallel group study to investigate the dose equivalence of Dysport and Botox in the treatment of cervical dystonia. J Neurol Neurosurg Psychiatry 1998;64(1):6Y12.
29. Comella CL, Jankovic J, Shannon KM, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology 2005;65(9):1423Y1429.
30. Scott AB, Suzuki D. Systemic toxicity of botulinum toxin by intramuscular injection in the monkey. Mov Disord 1988;3(4):333Y335.
31. Bakheit AM, Severa S, Cosgrove A, et al. Safety profile and efficacy of botulinum toxin A (Dysport) in children with muscle spasticity. Dev Med Child Neurol 2001;43(4):234Y238.
32. Albavera-Hernandez C, Rodriguez JM, Idrovo AJ. Safety of botulinum toxin type A among children with spasticity secondary to cerebral palsy: a systematic review of randomized clinical trials. Clin Rehabil 2009;23(5):394Y407.